An official website of the United States government
Publication Information
Affiliation
Department of Epidemiology and Biostatistics, University of California, San Francisco, California.; Departments of Medicine and Anesthesia, University of California, San Francisco, California.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.; Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, New York.; Department of Medicine, Epidemiology and Biostatistics, Western University, London, Ontario, Canada.; Division of Nephrology, University of Washington, Seattle, Washington.; Division of Nephrology and Hypertension and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee.; Renal Section, Veterans Affairs New York Harbor Healthcare System and New York University School of Medicine, New York, New York.; Division of Kidney, Urologic and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.; Division of Nephrology, Johns Hopkins School of Medicine, Baltimore, Maryland.; Division of Nephrology and Hypertension and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee.; Departments of Medicine and Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee.; Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, Pennsylvania.; Division of Nephrology, University of California, San Francisco School of Medicine, San Francisco, California.
Authors
Brar Sandeep, Liu Kathleen D, Go Alan S, Hsu Raymond K, Chinchilli Vernon M, Coca Steven G, Garg Amit X, Himmelfarb Jonathan, Ikizler T Alp, Kaufman James, Kimmel Paul L, Parikh Chirag R, Siew Edward D, Ware Lorraine B, Zeng Hui, Hsu Chi-Yuan
Studies
Abstract
The risk-benefit ratio of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy after AKI may be altered due to concerns regarding recurrent AKI. We evaluated, in a prospective cohort, the association between use (versus nonuse) of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and the subsequent risk of AKI and other adverse outcomes after hospitalizations with and without AKI.